Option chain shows key data for Artiva Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Artiva Biotherapeutics.

Artiva Biotherapeutics (NASDAQ:ARTV) Stock, Option Chain

Artiva Biotherapeutics

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

GoldmanSachs.Shutterstock

News

Price Target

Markets

Analyst Ratings

Trading Ideas

AKYA

ARTV

LUNR

QTRX

Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday

Chicago,,Il,-,July,27,,2017:,American,Airlines,Plane,On

Upgrades

Pre-Market Outlook

ARQT

CTXR

NUVL

This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

Stock market analysts

Initiation

MTVA

This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics Inc

Press Releases

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Management

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Earnings

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Health Care

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

ALLO

CDXS

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Avalo Therapeutics

Cabaletta Bio

CytomX Therapeutics

Citius Oncology

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

Immix Biopharma

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Metagenomi

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Exicure

Needham

HC Wainwright & Co.

Wedbush

Cantor Fitzgerald

Comments

Artiva Biotherapeutics

Artiva Biotherapeutics (ARTV) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell